Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;33(6):7545-7554.
doi: 10.1096/fj.201802652RR. Epub 2019 Mar 20.

Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice

Affiliations

Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice

Atsushi Sawada et al. FASEB J. 2019 Jun.

Abstract

Interventions that preserve motor neurons or restore functional motor neuroplasticity may extend longevity in amyotrophic lateral sclerosis (ALS). Delivery of neurotrophins may potentially revive degenerating motor neurons, yet this approach is dependent on the proper subcellular localization of neurotrophin receptor (NTR) to plasmalemmal signaling microdomains, termed membrane/lipid rafts (MLRs). We previously showed that overexpression of synapsin-driven caveolin-1 (Cav-1) (SynCav1) increases MLR localization of NTR [e.g., receptor tyrosine kinase B (TrkB)], promotes hippocampal synaptic and neuroplasticity, and significantly improves learning and memory in aged mice. The present study crossed a SynCav1 transgene-positive (SynCav1+) mouse with the mutant human superoxide dismutase glycine to alanine point mutation at amino acid 93 (hSOD1G93A) mouse model of ALS. When compared with hSOD1G93A, hSOD1G93A/SynCav1+ mice exhibited greater body weight and longer survival as well as better motor function. Microscopic analyses of hSOD1G93A/SynCav1+ spinal cords revealed preserved spinal cord α-motor neurons and preserved mitochondrial morphology. Moreover, hSOD1G93A/SynCav1+ spinal cords contained more MLRs (cholera toxin subunit B positive) and MLR-associated TrkB and Cav-1 protein expression. These findings demonstrate that SynCav1 delays disease progression in a mouse model of ALS, potentially by preserving or restoring NTR expression and localization to MLRs.-Sawada, A., Wang, S., Jian, M., Leem, J., Wackerbarth, J., Egawa, J., Schilling, J. M., Platoshyn, O., Zemljic-Harpf, A., Roth, D. M., Patel, H. H., Patel, P. M., Marsala, M., Head, B. P. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice.

Keywords: MLR; TrkB; mitochondria; motor neurons; neuroplasticity.

PubMed Disclaimer

Conflict of interest statement

The authors thank Ying Jones, Vanessa Taupin, and Timo Meerlo [University of California–San Diego (UCSD) Electron Microscopy Core] for preparation of the spinal cord samples and training on electron microscopy. The authors also thank Dr. Marilyn Farquhar (UCSD) for consultation on the project. The electron micrographs were taken in the Cellular and Molecular Medicine Electron Microscopy Core Facility, which is supported, in part, by the U.S. National Institutes of Health (NIH) Office of the Director Award S10OD023527. Work in the researchers’ laboratories was supported by a Veteran Affairs Merit Award from the Department of Veterans Affairs BX003671 (to B.P.H.), BX000783 (to D.M.R.), and BX001963 (to H.H.P.), and NIH National Institute of Neurological Disorders and Stroke Grant NS073653 (to B.P.H.), NIH National Heart, Lung, and Blood Institute Grants HL091071 and HL107200 (to H.H.P.), and NIH National Institute of General Medical Sciences Grant GM085179 (to P.M.P.). D.M.R., P.M.P., H.H.P., and B.P.H. are scientific founders of CavoGene LifeSciences LLC, and hold equity interest in the company. A.S. and S.W. share equal first authorship. The authors declare no other conflicts of interest.

Figures

Figure 1
Figure 1
SOD1G93A/SynCav1+ mice exhibit preserved body weight and greater longevity. A) Body weight curves for Tg-neg, SynCav1+, SOD1G93A, and SOD1G93A/SynCav1+ (n = 20/group). Data are expressed as means ± sem. **P < 0.01, ***P < 0.001 vs. SOD1G93A. Two-way ANOVA with Tukey’s multiple comparisons post hoc test with significance set at P < 0.05. B) Kaplan-Meier survival curve of male SOD1G93A (n = 19) and SOD1G93A/SynCav1+ (n = 17) mice. Mean survival (mean ± sem): SOD1G93A/SynCav1+, 180.3 ± 4.5 d; SOD1G93A, 155.5 ± 4.4 d; P = 0.0004, unpaired Student’s t test. Median survival: SOD1G93A/SynCav1+, 182 d; SOD1G93A, 153 d; P = 0.0006, unpaired Student’s t test (log-rank Mantel-Cox test).
Figure 2
Figure 2
SOD1G93A/SynCav1+ mice exhibit greater MEPs in upper and lower limbs. To identify conductivity of descending motor axons, MEPs were elicited by electrical stimulation of motor cortex and extrapyramidal system and responses recorded in upper trapezius or lower gastrocnemius muscles. A) Amplitude of MEP from upper limb. B) Amplitude (mV) of MEP from lower limb (gastrocnemius muscle). C) Latency (ms) of MEP from lower limb. D) Resting EMG (mVs) from lower limb. Two-way ANOVA with Tukey’s multiple comparison post hoc test. All data are expressed as means ± sem. (n = 9–10/group). *P < 0.05, **P < 0.01, ***P < 0.001 vs. SOD1G93A.
Figure 3
Figure 3
SOD1G93A/SynCav1+ mice perform better on voluntary running wheel (RW) task. The 12-wk (AC) and 16-wk (DF) mean RW velocity (m/s) and total distance (m) for 36 h. Data are expressed as means ± sem. (n = 9–10/group). One-way ANOVA with Tukey’s multiple comparisons post hoc test with significance set at P < 0.05. **P < 0.01, ****P < 0.0001.
Figure 4
Figure 4
SOD1G93A/SynCav1+ mice display more ChAT-positive α-motor neurons in spinal ventral horn column at 12 wk. A) Immunofluorescence confocal microscopy for ChAT-positive neurons in cervical (C3), thoracic (T1), and lumbar (L4) spinal cord at 12 wk. Scale bars, 50 μm. BD) Quantitation of total number of α-motor neurons in C3 (B), T1 (C), and L4 (D) ventral horn segments from the spinal cord. Data are expressed as means ± sem. (n = 4/group). N.s., not significant. One-way ANOVA with Tukey’s multiple comparisons post hoc test with significance set at P < 0.05. **P < 0.01.
Figure 5
Figure 5
SOD1G93A/SynCav1+ mice have increased MLR and MLR-localized TrkB in spinal cord tissue. A) Immunoblot of TrkB, Cav-1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in spinal cord homogenates from Tg-neg, SOD1G93A, and SOD1G93A/SynCav1+ at 12 wk. B) quantitation of data in A. C) Spinal cord tissue subjected to sucrose density fractionation followed by immunoblot of TrkB, CT-B, and Cav-1. D) quantitation of data in C. All fractions (4–12) were generated from equal protein loading of 0.5 mg/ml. Red line indicates buoyant fractions 4 and 5. Data represent arbitrary units (A.U.) means ± sem. (n = 4/group). One-way ANOVA with Tukey’s multiple comparisons post hoc test with significance set at P < 0.05. *P < 0.05, **P < 0.01, ****P < 0.0001.
Figure 6
Figure 6
SOD1G93A/SynCav1+ mice exhibit preserved mitochondrial morphology L4 ventral horn motor neurons. A) Electron micrographs of motor neuron mitochondria cross sections of spinal cords from lumbar L4 ventral horn of wild-type (Tg-neg; first panel), hSOD1G93A (second panel), SynCav1+ (third panel), and hSOD1G93A/SynCav1+ (fourth panel) mice. Scale bars, 1 µm. B) Quantitation of average cristae area density, mitochondrial perimeter, and area. Data represent means ± sem. (n = 3/group). One-way ANOVA with Tukey’s multiple comparisons post hoc test with significance set at P < 0.05. #P < 0.05.

Similar articles

Cited by

References

    1. Kiernan M. C., Vucic S., Cheah B. C., Turner M. R., Eisen A., Hardiman O., Burrell J. R., Zoing M. C. (2011) Amyotrophic lateral sclerosis. Lancet 377, 942–955 - PubMed
    1. Keifer O. P., Jr., O’Connor D. M., Boulis N. M. (2014) Gene and protein therapies utilizing VEGF for ALS. Pharmacol. Ther. 141, 261–271 - PMC - PubMed
    1. O’Connor D. M., Boulis N. M. (2015) Gene therapy for neurodegenerative diseases. Trends Mol. Med. 21, 504–512; erratum: 22, 266 - PubMed
    1. Brown R. H., Al-Chalabi A. (2017) Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162–172 - PubMed
    1. Hardiman O., van den Berg L. H. (2017) Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 16, 490–491 - PubMed

Publication types